Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708169 | 0.87 | TSHR (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL661214 | 0.87 | TSHR (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2328981 | 0.80 | PRMT5 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4023237 | 0.78 | TSHR (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3372522 | 0.78 | DRD2 (0.44) | ADRA1ATSHRCYP19A1CYP1A2POLB | |
| SCHEMBL661994 | 0.75 | CYP2A6 (0.44) | ADRA1AHPGDTSHRCYP19A1CYP11B1 | |
| SCHEMBL664099 | 0.75 | CYP19A1 (0.43) | HPGDTSHRCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL27906419 | 0.74 | TBXAS1 (0.38) | ADRA1ACYP19A1CYP1A2POLBCYP3A4 | |
| SCHEMBL662144 | 0.74 | CYP11B1 (0.45) | HPGDTSHRCYP3A4CYP11B1CYP11B2 | |
| SCHEMBL664179 | 0.74 | CYP11B1 (0.45) | HPGDTSHRCYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| EP-3827820-A1 | BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3610890-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806717-B2 | Methods and compositions for improving cognitive function | GRIN2A, CHRNA2, SYNGR2 | SRD5A1 2328/4885ADRA1A 2822/4885CHRM2 177/4885 |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | SRD5A1 1497/4885ADRA1A 936/4885CHRM2 308/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | SRD5A1 2328/4885ADRA1A 2822/4885CHRM2 177/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | SRD5A1 3829/4885ADRA1A 556/4885CHRM2 97/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | SRD5A1 2033/4885ADRA1A 878/4885CHRM2 342/4885 |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | SRD5A1 1381/4885ADRA1A 385/4885CHRM2 173/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | SRD5A1 2328/4885ADRA1A 2822/4885CHRM2 177/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | SRD5A1 3057/4885ADRA1A 894/4885CHRM2 194/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | SRD5A1 3057/4885ADRA1A 894/4885CHRM2 194/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | SRD5A1 2370/4885ADRA1A 1433/4885CHRM2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.